Skip to content

Liver protective efficacy of a Polyherbal formulation in Liver injury.

Determination of the Hepatoprotective Activity of a Traditional Compound Herbal Formulation for the Treatment of Yakrit Vikara w.s.r.to Drug Induced Hepatic Injury: A Pre-Clinical and Clinical Study - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/086565
Enrollment
30
Registered
2025-05-08
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K719- Toxic liver disease, unspecified

Interventions

None listed

Sponsors

Institute of Post Graduate Ayurvedic Education and Research at SVSP Hospital,Govt.of West Bengal.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjective parameter- The patient who will agree to follow the study protocol of the informed consent letter. The patient having the following signs and symptoms for than 2 to 3 months-any of 3 symptoms 1.Agnimanda -impaired digestive power 2. Arochaka -loss of appetite 3.Ajirna-indigestion 4. Sula -pain in the abdomen 5. Adhman flatulence 6. Vitvikara -impaired bowel habit 7.Hrillas-nausea Objective parameter -any of 2 parameter Selection of the patient based on LFT Total bilirubin- greater than 1.0 mg/dl Alanine transaminase -greater than 56 IU/L Aspartate transaminase -greater than 35 IU/L Alkaline phosphatase -greater than 133 IU/L Impaired AST: ALT ratio

Exclusion criteria

Exclusion criteria: Age below 30 yrs. or above 60 yrs. Pre- existing Diabetes and other systemic disorders. History of Trauma. Pregnancy and Lactating mother. Malignancy of Liver,Hepatitis B,Cirrhosis of liver, Gilberts disease.

Design outcomes

Primary

MeasureTime frame
The primary outcome will be measured based on clinical, biochemical,Haematological outcome safety and tolerability measures to determine the effectiveness and safety of the test drugs in the patients suffering from drug induced lived diseases.Timepoint: 56 days

Secondary

MeasureTime frame
The effect of the test drug medication alters the quality of life that will be evaluated after the completion of the treatment.Timepoint: 56 days

Countries

India

Contacts

Public ContactIndu Singh

Institute of Post Graduate Ayurvedic Education and Research at S.V.S.P. Hospital .

dr.sureshkjaiswara@gmail.com9681098261

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026